One limitation of EPIC-seq is its reliance on prior knowledge of genes associated with specific cancers. The effectiveness of the EPIC-seq model hinges on the availability of comprehensive gene expression profiles for the targeted cancer types. This dependency may restrict its applicability to cancers with well-characterized gene expression patterns, limiting its utility in cancers with less understood molecular signatures.